Vaxart (OTCMKTS:VXRT) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Vaxart, Inc. (OTCMKTS:VXRT) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.58 and traded as low as $0.58. Vaxart shares last traded at $0.6001, with a volume of 682,120 shares.

Vaxart Stock Performance

The firm’s 50 day moving average is $0.68 and its two-hundred day moving average is $0.58. The stock has a market capitalization of $145.25 million, a PE ratio of 4.00 and a beta of 1.10.

Vaxart (OTCMKTS:VXRT) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02. Vaxart had a net margin of 14.51% and a return on equity of 61.43%. The firm had revenue of $39.23 million for the quarter, compared to the consensus estimate of $50.50 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. grew its holdings in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 34,075 shares in the last quarter. Marshall Wace LLP acquired a new position in Vaxart during the 2nd quarter worth approximately $794,000. Creative Planning acquired a new position in Vaxart during the 2nd quarter worth approximately $33,000. Goldman Sachs Group Inc. acquired a new position in shares of Vaxart in the 1st quarter valued at $31,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares in the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.